{"ticker": {"uuid": "3b608633-db68-4741-a649-3406e96677e8", "symbol": "AGMB", "name": "AgomAb Therapeutics NV American Depositary Shares", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Enterprise value to EBIT forward of AgomAb Therapeutics NV \u2013 NASDAQ:AGMB", "summary": "This article provides access to the \"Enterprise value to EBIT forward\" metric for AgomAb Therapeutics NV (NASDAQ:AGMB) on TradingView. It indicates that the market is currently closed with no trades recorded. The content is primarily a gateway to financial data and tools offered ", "url": "https://www.tradingview.com/symbols/NASDAQ-AGMB/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-07-11T10:40:55", "published_display": "11 Jul 2026 10:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of AgomAb Therapeutics NV \u2013 NASDAQ:AGMB", "summary": "This page provides financial data specifically regarding the \"Price to book forward\" for AgomAb Therapeutics NV (NASDAQ: AGMB). The article states that the market is currently closed with no trades recorded. It indicates that the data is provided by ICE Data Services and FactSet,", "url": "https://www.tradingview.com/symbols/NASDAQ-AGMB/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-07T02:40:58", "published_display": "07 Jul 2026 02:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is AgomAB Therapeutics NV (AGMB) Stock a Biotech Opportunity With Targeted Tissue Therapy Potential?", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxNV1otalZiZW9pc2Q5YnB0aGE1ZGZaX2VlMVlna1Qzank5VWRWckRwdERrelJKcEhRYl9kOHJrZUdrWi0ta2lGSExGTUw0MFcyZG9qX3NWYm9nUHpFdHpxbmp4cHhjVWd5WlE5eEVNQk9lSUNNSVRNWE1LcFlPbGwybm1YUzdUeGk2QVB2UXZPMnFIeEdfVUVpRDNR?oc=5", "source_name": "Market source", "published_at": "2026-07-02T07:00:00+00:00", "published_display": "02 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AGMB - AgomAb Therapeutics NV ADR Short Interest", "summary": "This article provides a detailed overview of AgomAb Therapeutics NV ADR (AGMB) stock performance and financial data. It includes key metrics such as market capitalization, enterprise value, various financial ratios, and short interest details, alongside recent stock performance a", "url": "https://finviz.com/stock?t=AGMB&p=w&b=1&ty=si", "source_name": "Finviz", "published_at": "2026-07-01T20:40:51", "published_display": "01 Jul 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AGMB - AgomAb Therapeutics NV ADR Latest SEC Filings", "summary": "This article provides the latest SEC filing information for AgomAb Therapeutics NV ADR (AGMB). It includes a comprehensive overview of financial data, key metrics, stock performance, and insider/institutional ownership details for the company as of July 10.", "url": "https://finviz.com/stock?t=AGMB&ty=lf", "source_name": "Finviz", "published_at": "2026-06-26T23:39:55", "published_display": "26 Jun 2026 23:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "European Equities Traded in the US as American Depositary Receipts Decline Friday", "summary": "", "url": "https://finance.yahoo.com/markets/world-indices/articles/european-equities-traded-us-american-150622718.html", "source_name": "MT Newswires", "published_at": "2026-06-26T15:06:22+00:00", "published_display": "26 Jun 2026 15:06", "sentiment": "negative", "sentiment_pct": 42, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AgomAb Therapeutics NV ADR Actuals & Estimates (NASDAQ:AGMB)", "summary": "This article provides access to the financial actuals and estimates for AgomAb Therapeutics NV (NASDAQ:AGMB) on TradingView. It allows users to explore reported financial data and analyst estimates across various financial statements and metrics. The platform enables comparison o", "url": "https://www.tradingview.com/symbols/NASDAQ-AGMB/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-25T23:10:03", "published_display": "25 Jun 2026 23:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AGMB Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a price target for AgomAb Therapeutics NV (AGMB) for 2027, based on analysis from 5 analysts. It indicates a price target of 32.21, with no specific max or min estimates given by the analysts. The content emphasizes that this information is not investment ad", "url": "https://www.tradingview.com/symbols/NASDAQ-AGMB/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T18:10:03", "published_display": "25 Jun 2026 18:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Agomab Announces Design of NOV-ERA Phase 2b Study with Ontunisertib in Fibrostenosing Crohn\u2019s Disease", "summary": "Agomab Therapeutics has announced the design of its Phase 2b NOV-ERA study for ontunisertib, an investigational oral therapy for Fibrostenosing Crohn\u2019s Disease (FSCD). The company has aligned with the FDA on key study elements, including a novel primary endpoint of endoscopic pas", "url": "https://www.taiwannews.com.tw/news/6388347", "source_name": "Taiwan News", "published_at": "2026-06-24T17:10:49", "published_display": "24 Jun 2026 17:10", "sentiment": "positive", "sentiment_pct": 70, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 6K Agomab Therapeutics Nv For: 23 June By Investing.com", "summary": "Agomab Therapeutics Nv has filed a Form 6K for June 23. This filing is a routine report indicating corporate actions or financial updates from the company. The stock symbol for Agomab Therapeutics Nv is AGMB.", "url": "https://ng.investing.com/news/stock-market-news/form-6k-agomab-therapeutics-nv-for-23-june-93CH-2570792", "source_name": "Investing.com Nigeria", "published_at": "2026-06-24T05:40:07", "published_display": "24 Jun 2026 05:40", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Agomab Therapeutics Shares NOV-ERA Phase 2b Study Design With Ontunisertib in Fibrostenosing Crohn's Disease", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/agomab-therapeutics-shares-nov-era-213229077.html", "source_name": "MT Newswires", "published_at": "2026-06-23T21:32:29+00:00", "published_display": "23 Jun 2026 21:32", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Agomab\u2019s Crohn\u2019s study targets an endoscopic pass-through test", "summary": "Agomab (Nasdaq: AGMB) has announced the design for its NOV-ERA Phase 2b study of ontunisertib, an oral ALK5 inhibitor, for fibrostenosing Crohn's disease (FSCD). The study, which has aligned with the FDA on its design and primary endpoint of endoscopic passability at Week 24, wil", "url": "https://www.stocktitan.net/news/AGMB/agomab-announces-design-of-nov-era-phase-2b-study-with-ontunisertib-9n7fz9m8s2nz.html", "source_name": "Stock Titan", "published_at": "2026-06-23T20:10:22", "published_display": "23 Jun 2026 20:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Agomab (AGMB) sets FDA-aligned Phase 2b trial for fibrostenosing Crohn\u2019s", "summary": "Agomab Therapeutics (AGMB) has detailed the design of its FDA-aligned Phase 2b NOV-ERA trial for ontunisertib, targeting fibrostenosing Crohn\u2019s disease (FSCD), a condition affecting 46% of Crohn's patients with no approved drug treatments. The study, set to enroll up to 320 adult", "url": "https://www.stocktitan.net/sec-filings/AGMB/6-k-agomab-therapeutics-nv-current-report-foreign-issuer-0db9eaa83567.html", "source_name": "Stock Titan", "published_at": "2026-06-23T20:10:22", "published_display": "23 Jun 2026 20:10", "sentiment": "positive", "sentiment_pct": 62, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright initiates Agomab stock coverage with buy rating By Investing.com", "summary": "H.C. Wainwright has initiated coverage on Agomab Therapeutics (NASDAQ:AGMB) with a buy rating and a price target of $35, citing significant upside potential from its current trading price of $10.98. The firm highlighted Agomab's promising pipeline of organ-restricted inhibitors f", "url": "https://ng.investing.com/news/stock-market-news/hc-wainwright-initiates-agomab-stock-coverage-with-buy-rating-93CH-2567239", "source_name": "Investing.com Nigeria", "published_at": "2026-06-22T16:41:07", "published_display": "22 Jun 2026 16:41", "sentiment": "positive", "sentiment_pct": 82, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AGMB SEC Filings - AgomAb Therapeutics NV 10-K, 10-Q, 8-K Forms", "summary": "This page provides a comprehensive overview of AgomAb Therapeutics NV (AGMB) SEC filings, including annual reports, quarterly earnings, and material event disclosures. It highlights key recent filings such as LSP 7's 10.6% stake acquisition and the completion and filing details o", "url": "https://www.stocktitan.net/sec-filings/AGMB/page-3.html", "source_name": "Stock Titan", "published_at": "2026-06-08T23:09:35", "published_display": "08 Jun 2026 23:09", "sentiment": "positive", "sentiment_pct": 66, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AgomAb Therapeutics: High Risk, High Reward Stock (NASDAQ:AGMB)", "summary": "", "url": "https://news.google.com/rss/articles/CBMikgFBVV95cUxOaW5WMDMwd3R6dXE0eVdUdEJoTFNrX3lPdG9wcXNtazJqRGZMeTlBQzc0SExyNVFXNmU4N3RpaHVxRlVDeU1sRTAxZmdPaTFtUDFLRlB3OEhIMm5MVW1iUjlxb1dkRVM1aUNjZXB4OHNRZEt0MU5ydG10NWg0a1Jja1Q3emNzUnR0RkdGaFBpbl9GZw?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-04T07:00:00+00:00", "published_display": "04 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AGMB - AgomAb Therapeutics NV ADR Stock Price and Quote", "summary": "This article provides a comprehensive overview of AgomAb Therapeutics NV (AGMB) ADR stock, including its current price, key financial metrics, analyst ratings, and recent news. It highlights the company's focus on developing therapies for immunology and inflammatory diseases and ", "url": "https://finviz.com/stock?t=AGMB", "source_name": "Finviz", "published_at": "2026-05-29T19:40:56", "published_display": "29 May 2026 19:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "All AGM agenda items approved at Agomab Therapeutics (NASDAQ: AGMB)", "summary": "Agomab Therapeutics (NASDAQ: AGMB) announced that all agenda items presented at its Annual General Meeting on May 26, 2026, were approved. The company filed a Form 6-K to formally report these results, including the approval of financial statements, discharge of directors and aud", "url": "https://www.stocktitan.net/sec-filings/AGMB/6-k-agomab-therapeutics-nv-current-report-foreign-issuer-b4d61b059e05.html", "source_name": "Stock Titan", "published_at": "2026-05-27T11:09:37", "published_display": "27 May 2026 11:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Shareholders back all Agomab proposals, reappoint 2 directors", "summary": "Agomab Therapeutics NV announced that its shareholders approved all agenda items at the Annual General Meeting held on May 26, 2026. This included the approval of the 2025 financial statements, the discharge of directors and the auditor, and the reappointments of Ohad Hammer and ", "url": "https://www.stocktitan.net/news/AGMB/agomab-announces-results-of-annual-general-ci4bpbhewfg6.html", "source_name": "Stock Titan", "published_at": "2026-05-27T09:09:38", "published_display": "27 May 2026 09:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Press Release: Agomab Announces Results of Annual General Meeting", "summary": "Agomab Therapeutics NV announced the results of its Annual General Meeting of Shareholders, held on May 27, 2026. All proposed resolutions were approved by shareholders, including the re-election of Deloitte Bedrijfsrevisoren BV as statutory auditor. The company confirmed the com", "url": "https://www.moomoo.com/news/post/70627563/press-release-agomab-announces-results-of-annual-general-meeting?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-05-27T09:09:37", "published_display": "27 May 2026 09:09", "sentiment": "positive", "sentiment_pct": 69, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Agomab Announces Results of Annual General Meeting", "summary": "Agomab Therapeutics NV announced the results of its Annual General Meeting (AGM) held on May 26, 2026. All agenda items were approved, including the financial statements for 2025, discharge of directors and auditor, and the reappointment of Mr. Ohad Hammer and Mr. Tim Knotnerus t", "url": "https://www.manilatimes.net/2026/05/27/tmt-newswire/globenewswire/agomab-announces-results-of-annual-general-meeting/2352371/amp", "source_name": "The Manila Times", "published_at": "2026-05-27T09:09:37", "published_display": "27 May 2026 09:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Redmile (AGMB) holds 2.74M shares, a 5.6% stake in AgomAb", "summary": "Redmile Group, LLC has reported a beneficial ownership of 2,735,926 Common Shares, representing a 5.6% stake in AgomAb Therapeutics NV (AGMB). This holding is composed of 2,579,676 Common Shares and 156,250 American Depositary Shares (ADS), with Redmile Biopharma Investments III,", "url": "https://www.stocktitan.net/sec-filings/AGMB/schedule-13g-agomab-therapeutics-nv-passive-investment-disclosure-5-3970218f3659.html", "source_name": "Stock Titan", "published_at": "2026-05-16T00:40:05", "published_display": "16 May 2026 00:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cormorant reports 2.47M ADS stake in Agomab (NASDAQ: AGMB)", "summary": "Cormorant Asset Management and Bihua Chen have filed a Schedule 13G, reporting a beneficial ownership of 2,465,348 American Depositary Shares (ADS) in Agomab Therapeutics NV (NASDAQ: AGMB), representing 5.01% of the common stock outstanding as of March 31, 2026. This filing indic", "url": "https://www.stocktitan.net/sec-filings/AGMB/schedule-13g-agomab-therapeutics-nv-passive-investment-disclosure-5-2b563c184518.html", "source_name": "Stock Titan", "published_at": "2026-05-16T00:40:05", "published_display": "16 May 2026 00:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Agomab to showcase IPF candidate AGMB-447 at ATS and investor events", "summary": "Agomab Therapeutics announced its participation in several scientific and investor conferences in 2026. The company will present a poster on its idiopathic pulmonary fibrosis (IPF) candidate, AGMB-447, at the ATS International Conference, detailing preclinical and healthy subject", "url": "https://www.stocktitan.net/news/AGMB/agomab-to-participate-in-upcoming-bxde5pl16l9j.html", "source_name": "Stock Titan", "published_at": "2026-05-15T01:09:56", "published_display": "15 May 2026 01:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Agomab to Participate in Upcoming Conferences", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/agomab-participate-upcoming-conferences-113000240.html", "source_name": "GlobeNewswire", "published_at": "2026-05-14T11:30:00+00:00", "published_display": "14 May 2026 11:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Number of shareholders of AgomAb Therapeutics NV \u2013 NASDAQ:AGMB", "summary": "This page from TradingView provides information about AgomAb Therapeutics NV (NASDAQ:AGMB), specifically focusing on the number of shareholders. It indicates that the market for AGMB is currently closed, and presents a section for charting the period, value, and percentage change", "url": "https://www.tradingview.com/symbols/NASDAQ-AGMB/financials-statistics-and-ratios/number-of-shareholders/", "source_name": "TradingView", "published_at": "2026-05-09T06:40:11", "published_display": "09 May 2026 06:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How AgomAb (AGMB) differentiates itself from competitors (+6.22%) 2026-05-08 - MAMA Signal", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxObjBQczN0Sk5yXzhoX2t6c0NxMzkwOGhyYmZzeDhzZC00eFh5UkVrMDhIaGs5eXFobXB2RUNsTlFIWVdjS05qNDZRbS1vQnhrVDFObFY4WUhMTEtOa0tKWEVPR2hKWFdkQ3dfVkJ4LXJJRGN3NHV5WjlNUEJNS0k2akdMeTRmN3RNd0Z2TkhmQnBsZTZYcXFLOU1SSnc4bkdVTVJoeWVsTkhzQkVINzdR?oc=5", "source_name": "dars.gov.et", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Agomab Posts 2025 Loss, Fortifies Cash After IPO and Targets Key 2026 Trial Milestones", "summary": "Agomab Therapeutics NV ADR (AGMB) reported a \u20ac62.5 million net loss in 2025 but significantly strengthened its cash reserves to \u20ac116.5 million, further bolstered by $208 million from its February 2026 IPO, extending its cash runway into mid-2029. The biopharma company plans to in", "url": "https://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/1520137/agomab-posts-2025-loss-fortifies-cash-after-ipo-and-targets-key-2026-trial-milestones/", "source_name": "The Globe and Mail", "published_at": "2026-04-26T06:40:11", "published_display": "26 Apr 2026 06:40", "sentiment": "positive", "sentiment_pct": 66, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "IPO cash extends Agomab (Nasdaq: AGMB) runway and backs 2026 trials", "summary": "Agomab Therapeutics (AGMB) reported full-year 2025 results, showing a net loss of \u20ac62.5 million but a significantly strengthened balance sheet after raising $208 million gross proceeds from its February 2026 IPO. This funding is expected to extend the company's cash runway into t", "url": "https://www.stocktitan.net/sec-filings/AGMB/6-k-agomab-therapeutics-nv-current-report-foreign-issuer-5990fdc01deb.html", "source_name": "Stock Titan", "published_at": "2026-04-24T20:40:19", "published_display": "24 Apr 2026 20:40", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Agomab Reports Full Year 2025 Financial Results and Confirms 2026 Outlook", "summary": "Agomab Therapeutics NV reported its full-year 2025 financial results, highlighting significant clinical progress and strong financial positioning. The company secured \u20ac116.5 million in cash and cash investments by December 31, 2025, and an additional $208 million from its IPO in ", "url": "https://www.manilatimes.net/2026/04/24/tmt-newswire/globenewswire/agomab-reports-full-year-2025-financial-results-and-confirms-2026-outlook/2327687/amp", "source_name": "The Manila Times", "published_at": "2026-04-23T22:38:52", "published_display": "23 Apr 2026 22:38", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "After a $208M IPO, Agomab says cash lasts into 2029", "summary": "Agomab Therapeutics (NASDAQ: AGMB) reported its full-year 2025 financial results and reconfirmed its 2026 outlook. The company's cash and short-term investments of \u20ac116.5 million as of December 31, 2025, combined with $208 million gross IPO proceeds in February 2026, are expected", "url": "https://www.stocktitan.net/news/AGMB/agomab-reports-full-year-2025-financial-results-and-confirms-2026-b9h9mx75f1vn.html", "source_name": "Stock Titan", "published_at": "2026-04-23T22:38:52", "published_display": "23 Apr 2026 22:38", "sentiment": "positive", "sentiment_pct": 65, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Agomab Therapeutics Reports Strong Financial Position and Clinical Advancements Ahead of Phase 2 Trials in Fibrostenosing Crohn's Disease and Idiopathic Pulmonary Fibrosis", "summary": "Agomab Therapeutics announced strong financial results for 2025, with \u20ac116.5 million in cash and cash investments and $208 million raised from its IPO, extending its cash runway into the first half of 2029. The company made significant clinical progress, including positive FDA in", "url": "https://www.quiverquant.com/news/Agomab+Therapeutics+Reports+Strong+Financial+Position+and+Clinical+Advancements+Ahead+of+Phase+2+Trials+in+Fibrostenosing+Crohn's+Disease+and+Idiopathic+Pulmonary+Fibrosis", "source_name": "Quiver Quantitative", "published_at": "2026-04-23T22:20:00", "published_display": "23 Apr 2026 22:20", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "AgomAb Therapeutics (AGMB) Wins U.S. Patent for AGMB-447", "summary": "AgomAb Therapeutics NV (NASDAQ:AGMB) secured a U.S. patent for its investigational drug AGMB-447, an ALK5 inhibitor for idiopathic pulmonary fibrosis, providing protection through at least 2041. This news follows optimistic analyst coverage from Leerink and JPMorgan, who issued O", "url": "https://finance.yahoo.com/sectors/healthcare/articles/agomab-therapeutics-agmb-wins-u-184647133.html", "source_name": "Market source", "published_at": "2026-04-12T23:08:35", "published_display": "12 Apr 2026 23:08", "sentiment": "positive", "sentiment_pct": 74, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Agomab Therapeutics NV (AGMB) Stock Price Today: $12.31", "summary": "", "url": "https://news.google.com/rss/articles/CBMiV0FVX3lxTE5fWU12QldqQlFLc0pmVW5HMEhEXzhvcm9IcFhibmFZVU9XelRsUTlOV2Uxb0JEVGxZSng2NFZnT2JjQmpZMWtoYkJKdFJkRXFPODZvY2R3Yw?oc=5", "source_name": "Gotrade", "published_at": "2026-02-07T21:08:16+00:00", "published_display": "07 Feb 2026 21:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AgomAb Therapeutics NV Rings the Nasdaq Stock Market Closing Bell", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxQdU5zQ3Boa1lYSUlMU0lFSFp4Vk5IejFMcW1tNWVKTHRndFZIOFNrSFVZOGduSUZEcHVmM0VVTEh6OUhSWENyUk5qVkc3NG5nRUl1VEpTRDhJZnRtQjhDSmczNWgwemxUamZyV0MwczVlaU4tcXRKZzhTN01Tc2xadGV6MXhsTTdLaDJzOGJiUnl2ZndlNXc?oc=5", "source_name": "Nasdaq", "published_at": "2026-02-06T08:00:00+00:00", "published_display": "06 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AgomAb Therapeutics NV Rings the Closing Bell", "summary": "", "url": "https://news.google.com/rss/articles/CBMie0FVX3lxTFBIbXdTdnhSTDBVWk1FTlkwQTRnZTZDWk1PUDdFQ1ZBak4zV0lpS19ldUdfWFdLR3lEcnNsNWhjMGRyclNoTVJ2cGpuRWQ5RUs4clFUbmFtSV9JMkF0UjhhbUNjXzlfVXlUZ0p1eHZ5eW5pcVFhbTlNTzFvaw?oc=5", "source_name": "Nasdaq", "published_at": "2026-02-06T08:00:00+00:00", "published_display": "06 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Agomab, SpyGlass head to Nasdaq with IPOs totaling $350M", "summary": "", "url": "https://news.google.com/rss/articles/CBMijgFBVV95cUxPQmFIRVZ4VFhhQUNLU2pocGVCWUZPNkVIdjdtanZNMVlCUmNwWXdwejRSbWJkQmtuY2JoaEFXekQ3eW82WTFiOWhJQTBoVlBXZGNCMkJ1RExFUGFOX1pLT0ZVZEY5MWNFMVNUQUhHc1NvczByTWYxUVBERV81Q1NmcVFSSGp4b1NndjQ4eXlR?oc=5", "source_name": "Fierce Biotech", "published_at": "2026-02-06T08:00:00+00:00", "published_display": "06 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Agomab goes public on Nasdaq as biotech IPOs top $1bn in a single week", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxPNTFvbDFRNGlWNURySk5oRlBIZkNBeFNyNU9RWkZDYU9kMHRfNi1xRGRLTUluNHUwTFIyZG12YjBIbkIzLUhHZG8tVkRKb3VOemRTc3drNTE2V3dKU296enFmWTJYTjlEUXF4RUR1T2hMaG5kUG85dGgtbi15OU9PODVnYnBvSTA5Yjh6Y2oxR3dIdnlIZTdhREJRMUZyRk5kY0YxbGZSZjFTOGpoUm5nSmN1T0x6NGRV?oc=5", "source_name": "European Biotechnology Magazine", "published_at": "2026-02-06T08:00:00+00:00", "published_display": "06 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AgomAb Therapeutics NV (AGMB) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE40eVVER0FURm92V2JpLVpDeldmSU5PN3RMYjhWb0cwZVhIUk5hcGFYaUFiVWcwYm1jMHdGbTZVNHNKdmxwaUhGM0N2SlJxT1FhbW00?oc=5", "source_name": "Stock Titan", "published_at": "2026-02-06T04:27:58+00:00", "published_display": "06 Feb 2026 04:27", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AgomAb Therapeutics NV Readies US IPO On Early Promising Results (AGMB)", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxOZkMwUFZPcFY3WnkxaUdRaTBuLXo0MVVlN1RwUWY0Y3FKbTlOeVltWG40Q0tFdHlwMHpFNGVOQ201VzdEQl8xOGtEUE1LWl9OcTUtRDBfMEdtRm1qb0RzU0dTd0ppLTZlT2VnUERPYzkwYzV3eXZueXpKekhBS2pWVFltTEJ5SDRaWVJMU1FfZlJ5S3RTcXlkY3BuaVRBeDlhalpDVQ?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-01-29T08:00:00+00:00", "published_display": "29 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Enterprise value to EBIT forward of AgomAb Therapeutics NV \u2013 NASDAQ:AGMB", "summary": "This article provides access to the \"Enterprise value to EBIT forward\" metric for AgomAb Therapeutics NV (NASDAQ:AGMB) on TradingView. It indicates that the market is currently closed with no trades recorded. The content is primarily a gateway to financial data and tools offered ", "url": "https://www.tradingview.com/symbols/NASDAQ-AGMB/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-07-11T10:40:55", "published_display": "11 Jul 2026 10:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of AgomAb Therapeutics NV \u2013 NASDAQ:AGMB", "summary": "This page provides financial data specifically regarding the \"Price to book forward\" for AgomAb Therapeutics NV (NASDAQ: AGMB). The article states that the market is currently closed with no trades recorded. It indicates that the data is provided by ICE Data Services and FactSet,", "url": "https://www.tradingview.com/symbols/NASDAQ-AGMB/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-07T02:40:58", "published_display": "07 Jul 2026 02:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is AgomAB Therapeutics NV (AGMB) Stock a Biotech Opportunity With Targeted Tissue Therapy Potential?", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxNV1otalZiZW9pc2Q5YnB0aGE1ZGZaX2VlMVlna1Qzank5VWRWckRwdERrelJKcEhRYl9kOHJrZUdrWi0ta2lGSExGTUw0MFcyZG9qX3NWYm9nUHpFdHpxbmp4cHhjVWd5WlE5eEVNQk9lSUNNSVRNWE1LcFlPbGwybm1YUzdUeGk2QVB2UXZPMnFIeEdfVUVpRDNR?oc=5", "source_name": "Market source", "published_at": "2026-07-02T07:00:00+00:00", "published_display": "02 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AGMB - AgomAb Therapeutics NV ADR Short Interest", "summary": "This article provides a detailed overview of AgomAb Therapeutics NV ADR (AGMB) stock performance and financial data. It includes key metrics such as market capitalization, enterprise value, various financial ratios, and short interest details, alongside recent stock performance a", "url": "https://finviz.com/stock?t=AGMB&p=w&b=1&ty=si", "source_name": "Finviz", "published_at": "2026-07-01T20:40:51", "published_display": "01 Jul 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AGMB - AgomAb Therapeutics NV ADR Latest SEC Filings", "summary": "This article provides the latest SEC filing information for AgomAb Therapeutics NV ADR (AGMB). It includes a comprehensive overview of financial data, key metrics, stock performance, and insider/institutional ownership details for the company as of July 10.", "url": "https://finviz.com/stock?t=AGMB&ty=lf", "source_name": "Finviz", "published_at": "2026-06-26T23:39:55", "published_display": "26 Jun 2026 23:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "European Equities Traded in the US as American Depositary Receipts Decline Friday", "summary": "", "url": "https://finance.yahoo.com/markets/world-indices/articles/european-equities-traded-us-american-150622718.html", "source_name": "MT Newswires", "published_at": "2026-06-26T15:06:22+00:00", "published_display": "26 Jun 2026 15:06", "sentiment": "negative", "sentiment_pct": 42, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AgomAb Therapeutics NV ADR Actuals & Estimates (NASDAQ:AGMB)", "summary": "This article provides access to the financial actuals and estimates for AgomAb Therapeutics NV (NASDAQ:AGMB) on TradingView. It allows users to explore reported financial data and analyst estimates across various financial statements and metrics. The platform enables comparison o", "url": "https://www.tradingview.com/symbols/NASDAQ-AGMB/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-25T23:10:03", "published_display": "25 Jun 2026 23:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AGMB Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a price target for AgomAb Therapeutics NV (AGMB) for 2027, based on analysis from 5 analysts. It indicates a price target of 32.21, with no specific max or min estimates given by the analysts. The content emphasizes that this information is not investment ad", "url": "https://www.tradingview.com/symbols/NASDAQ-AGMB/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T18:10:03", "published_display": "25 Jun 2026 18:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Agomab Announces Design of NOV-ERA Phase 2b Study with Ontunisertib in Fibrostenosing Crohn\u2019s Disease", "summary": "Agomab Therapeutics has announced the design of its Phase 2b NOV-ERA study for ontunisertib, an investigational oral therapy for Fibrostenosing Crohn\u2019s Disease (FSCD). The company has aligned with the FDA on key study elements, including a novel primary endpoint of endoscopic pas", "url": "https://www.taiwannews.com.tw/news/6388347", "source_name": "Taiwan News", "published_at": "2026-06-24T17:10:49", "published_display": "24 Jun 2026 17:10", "sentiment": "positive", "sentiment_pct": 70, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 6K Agomab Therapeutics Nv For: 23 June By Investing.com", "summary": "Agomab Therapeutics Nv has filed a Form 6K for June 23. This filing is a routine report indicating corporate actions or financial updates from the company. The stock symbol for Agomab Therapeutics Nv is AGMB.", "url": "https://ng.investing.com/news/stock-market-news/form-6k-agomab-therapeutics-nv-for-23-june-93CH-2570792", "source_name": "Investing.com Nigeria", "published_at": "2026-06-24T05:40:07", "published_display": "24 Jun 2026 05:40", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Agomab Therapeutics Shares NOV-ERA Phase 2b Study Design With Ontunisertib in Fibrostenosing Crohn's Disease", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/agomab-therapeutics-shares-nov-era-213229077.html", "source_name": "MT Newswires", "published_at": "2026-06-23T21:32:29+00:00", "published_display": "23 Jun 2026 21:32", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Agomab\u2019s Crohn\u2019s study targets an endoscopic pass-through test", "summary": "Agomab (Nasdaq: AGMB) has announced the design for its NOV-ERA Phase 2b study of ontunisertib, an oral ALK5 inhibitor, for fibrostenosing Crohn's disease (FSCD). The study, which has aligned with the FDA on its design and primary endpoint of endoscopic passability at Week 24, wil", "url": "https://www.stocktitan.net/news/AGMB/agomab-announces-design-of-nov-era-phase-2b-study-with-ontunisertib-9n7fz9m8s2nz.html", "source_name": "Stock Titan", "published_at": "2026-06-23T20:10:22", "published_display": "23 Jun 2026 20:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Agomab (AGMB) sets FDA-aligned Phase 2b trial for fibrostenosing Crohn\u2019s", "summary": "Agomab Therapeutics (AGMB) has detailed the design of its FDA-aligned Phase 2b NOV-ERA trial for ontunisertib, targeting fibrostenosing Crohn\u2019s disease (FSCD), a condition affecting 46% of Crohn's patients with no approved drug treatments. The study, set to enroll up to 320 adult", "url": "https://www.stocktitan.net/sec-filings/AGMB/6-k-agomab-therapeutics-nv-current-report-foreign-issuer-0db9eaa83567.html", "source_name": "Stock Titan", "published_at": "2026-06-23T20:10:22", "published_display": "23 Jun 2026 20:10", "sentiment": "positive", "sentiment_pct": 62, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright initiates Agomab stock coverage with buy rating By Investing.com", "summary": "H.C. Wainwright has initiated coverage on Agomab Therapeutics (NASDAQ:AGMB) with a buy rating and a price target of $35, citing significant upside potential from its current trading price of $10.98. The firm highlighted Agomab's promising pipeline of organ-restricted inhibitors f", "url": "https://ng.investing.com/news/stock-market-news/hc-wainwright-initiates-agomab-stock-coverage-with-buy-rating-93CH-2567239", "source_name": "Investing.com Nigeria", "published_at": "2026-06-22T16:41:07", "published_display": "22 Jun 2026 16:41", "sentiment": "positive", "sentiment_pct": 82, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AGMB SEC Filings - AgomAb Therapeutics NV 10-K, 10-Q, 8-K Forms", "summary": "This page provides a comprehensive overview of AgomAb Therapeutics NV (AGMB) SEC filings, including annual reports, quarterly earnings, and material event disclosures. It highlights key recent filings such as LSP 7's 10.6% stake acquisition and the completion and filing details o", "url": "https://www.stocktitan.net/sec-filings/AGMB/page-3.html", "source_name": "Stock Titan", "published_at": "2026-06-08T23:09:35", "published_display": "08 Jun 2026 23:09", "sentiment": "positive", "sentiment_pct": 66, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AgomAb Therapeutics: High Risk, High Reward Stock (NASDAQ:AGMB)", "summary": "", "url": "https://news.google.com/rss/articles/CBMikgFBVV95cUxOaW5WMDMwd3R6dXE0eVdUdEJoTFNrX3lPdG9wcXNtazJqRGZMeTlBQzc0SExyNVFXNmU4N3RpaHVxRlVDeU1sRTAxZmdPaTFtUDFLRlB3OEhIMm5MVW1iUjlxb1dkRVM1aUNjZXB4OHNRZEt0MU5ydG10NWg0a1Jja1Q3emNzUnR0RkdGaFBpbl9GZw?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-04T07:00:00+00:00", "published_display": "04 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AGMB - AgomAb Therapeutics NV ADR Stock Price and Quote", "summary": "This article provides a comprehensive overview of AgomAb Therapeutics NV (AGMB) ADR stock, including its current price, key financial metrics, analyst ratings, and recent news. It highlights the company's focus on developing therapies for immunology and inflammatory diseases and ", "url": "https://finviz.com/stock?t=AGMB", "source_name": "Finviz", "published_at": "2026-05-29T19:40:56", "published_display": "29 May 2026 19:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "All AGM agenda items approved at Agomab Therapeutics (NASDAQ: AGMB)", "summary": "Agomab Therapeutics (NASDAQ: AGMB) announced that all agenda items presented at its Annual General Meeting on May 26, 2026, were approved. The company filed a Form 6-K to formally report these results, including the approval of financial statements, discharge of directors and aud", "url": "https://www.stocktitan.net/sec-filings/AGMB/6-k-agomab-therapeutics-nv-current-report-foreign-issuer-b4d61b059e05.html", "source_name": "Stock Titan", "published_at": "2026-05-27T11:09:37", "published_display": "27 May 2026 11:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Shareholders back all Agomab proposals, reappoint 2 directors", "summary": "Agomab Therapeutics NV announced that its shareholders approved all agenda items at the Annual General Meeting held on May 26, 2026. This included the approval of the 2025 financial statements, the discharge of directors and the auditor, and the reappointments of Ohad Hammer and ", "url": "https://www.stocktitan.net/news/AGMB/agomab-announces-results-of-annual-general-ci4bpbhewfg6.html", "source_name": "Stock Titan", "published_at": "2026-05-27T09:09:38", "published_display": "27 May 2026 09:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Press Release: Agomab Announces Results of Annual General Meeting", "summary": "Agomab Therapeutics NV announced the results of its Annual General Meeting of Shareholders, held on May 27, 2026. All proposed resolutions were approved by shareholders, including the re-election of Deloitte Bedrijfsrevisoren BV as statutory auditor. The company confirmed the com", "url": "https://www.moomoo.com/news/post/70627563/press-release-agomab-announces-results-of-annual-general-meeting?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-05-27T09:09:37", "published_display": "27 May 2026 09:09", "sentiment": "positive", "sentiment_pct": 69, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Agomab Announces Results of Annual General Meeting", "summary": "Agomab Therapeutics NV announced the results of its Annual General Meeting (AGM) held on May 26, 2026. All agenda items were approved, including the financial statements for 2025, discharge of directors and auditor, and the reappointment of Mr. Ohad Hammer and Mr. Tim Knotnerus t", "url": "https://www.manilatimes.net/2026/05/27/tmt-newswire/globenewswire/agomab-announces-results-of-annual-general-meeting/2352371/amp", "source_name": "The Manila Times", "published_at": "2026-05-27T09:09:37", "published_display": "27 May 2026 09:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Redmile (AGMB) holds 2.74M shares, a 5.6% stake in AgomAb", "summary": "Redmile Group, LLC has reported a beneficial ownership of 2,735,926 Common Shares, representing a 5.6% stake in AgomAb Therapeutics NV (AGMB). This holding is composed of 2,579,676 Common Shares and 156,250 American Depositary Shares (ADS), with Redmile Biopharma Investments III,", "url": "https://www.stocktitan.net/sec-filings/AGMB/schedule-13g-agomab-therapeutics-nv-passive-investment-disclosure-5-3970218f3659.html", "source_name": "Stock Titan", "published_at": "2026-05-16T00:40:05", "published_display": "16 May 2026 00:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cormorant reports 2.47M ADS stake in Agomab (NASDAQ: AGMB)", "summary": "Cormorant Asset Management and Bihua Chen have filed a Schedule 13G, reporting a beneficial ownership of 2,465,348 American Depositary Shares (ADS) in Agomab Therapeutics NV (NASDAQ: AGMB), representing 5.01% of the common stock outstanding as of March 31, 2026. This filing indic", "url": "https://www.stocktitan.net/sec-filings/AGMB/schedule-13g-agomab-therapeutics-nv-passive-investment-disclosure-5-2b563c184518.html", "source_name": "Stock Titan", "published_at": "2026-05-16T00:40:05", "published_display": "16 May 2026 00:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Agomab to showcase IPF candidate AGMB-447 at ATS and investor events", "summary": "Agomab Therapeutics announced its participation in several scientific and investor conferences in 2026. The company will present a poster on its idiopathic pulmonary fibrosis (IPF) candidate, AGMB-447, at the ATS International Conference, detailing preclinical and healthy subject", "url": "https://www.stocktitan.net/news/AGMB/agomab-to-participate-in-upcoming-bxde5pl16l9j.html", "source_name": "Stock Titan", "published_at": "2026-05-15T01:09:56", "published_display": "15 May 2026 01:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Agomab to Participate in Upcoming Conferences", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/agomab-participate-upcoming-conferences-113000240.html", "source_name": "GlobeNewswire", "published_at": "2026-05-14T11:30:00+00:00", "published_display": "14 May 2026 11:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Number of shareholders of AgomAb Therapeutics NV \u2013 NASDAQ:AGMB", "summary": "This page from TradingView provides information about AgomAb Therapeutics NV (NASDAQ:AGMB), specifically focusing on the number of shareholders. It indicates that the market for AGMB is currently closed, and presents a section for charting the period, value, and percentage change", "url": "https://www.tradingview.com/symbols/NASDAQ-AGMB/financials-statistics-and-ratios/number-of-shareholders/", "source_name": "TradingView", "published_at": "2026-05-09T06:40:11", "published_display": "09 May 2026 06:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How AgomAb (AGMB) differentiates itself from competitors (+6.22%) 2026-05-08 - MAMA Signal", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxObjBQczN0Sk5yXzhoX2t6c0NxMzkwOGhyYmZzeDhzZC00eFh5UkVrMDhIaGs5eXFobXB2RUNsTlFIWVdjS05qNDZRbS1vQnhrVDFObFY4WUhMTEtOa0tKWEVPR2hKWFdkQ3dfVkJ4LXJJRGN3NHV5WjlNUEJNS0k2akdMeTRmN3RNd0Z2TkhmQnBsZTZYcXFLOU1SSnc4bkdVTVJoeWVsTkhzQkVINzdR?oc=5", "source_name": "dars.gov.et", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Agomab Posts 2025 Loss, Fortifies Cash After IPO and Targets Key 2026 Trial Milestones", "summary": "Agomab Therapeutics NV ADR (AGMB) reported a \u20ac62.5 million net loss in 2025 but significantly strengthened its cash reserves to \u20ac116.5 million, further bolstered by $208 million from its February 2026 IPO, extending its cash runway into mid-2029. The biopharma company plans to in", "url": "https://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/1520137/agomab-posts-2025-loss-fortifies-cash-after-ipo-and-targets-key-2026-trial-milestones/", "source_name": "The Globe and Mail", "published_at": "2026-04-26T06:40:11", "published_display": "26 Apr 2026 06:40", "sentiment": "positive", "sentiment_pct": 66, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IPO cash extends Agomab (Nasdaq: AGMB) runway and backs 2026 trials", "summary": "Agomab Therapeutics (AGMB) reported full-year 2025 results, showing a net loss of \u20ac62.5 million but a significantly strengthened balance sheet after raising $208 million gross proceeds from its February 2026 IPO. This funding is expected to extend the company's cash runway into t", "url": "https://www.stocktitan.net/sec-filings/AGMB/6-k-agomab-therapeutics-nv-current-report-foreign-issuer-5990fdc01deb.html", "source_name": "Stock Titan", "published_at": "2026-04-24T20:40:19", "published_display": "24 Apr 2026 20:40", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Agomab Reports Full Year 2025 Financial Results and Confirms 2026 Outlook", "summary": "Agomab Therapeutics NV reported its full-year 2025 financial results, highlighting significant clinical progress and strong financial positioning. The company secured \u20ac116.5 million in cash and cash investments by December 31, 2025, and an additional $208 million from its IPO in ", "url": "https://www.manilatimes.net/2026/04/24/tmt-newswire/globenewswire/agomab-reports-full-year-2025-financial-results-and-confirms-2026-outlook/2327687/amp", "source_name": "The Manila Times", "published_at": "2026-04-23T22:38:52", "published_display": "23 Apr 2026 22:38", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "After a $208M IPO, Agomab says cash lasts into 2029", "summary": "Agomab Therapeutics (NASDAQ: AGMB) reported its full-year 2025 financial results and reconfirmed its 2026 outlook. The company's cash and short-term investments of \u20ac116.5 million as of December 31, 2025, combined with $208 million gross IPO proceeds in February 2026, are expected", "url": "https://www.stocktitan.net/news/AGMB/agomab-reports-full-year-2025-financial-results-and-confirms-2026-b9h9mx75f1vn.html", "source_name": "Stock Titan", "published_at": "2026-04-23T22:38:52", "published_display": "23 Apr 2026 22:38", "sentiment": "positive", "sentiment_pct": 65, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Agomab Therapeutics Reports Strong Financial Position and Clinical Advancements Ahead of Phase 2 Trials in Fibrostenosing Crohn's Disease and Idiopathic Pulmonary Fibrosis", "summary": "Agomab Therapeutics announced strong financial results for 2025, with \u20ac116.5 million in cash and cash investments and $208 million raised from its IPO, extending its cash runway into the first half of 2029. The company made significant clinical progress, including positive FDA in", "url": "https://www.quiverquant.com/news/Agomab+Therapeutics+Reports+Strong+Financial+Position+and+Clinical+Advancements+Ahead+of+Phase+2+Trials+in+Fibrostenosing+Crohn's+Disease+and+Idiopathic+Pulmonary+Fibrosis", "source_name": "Quiver Quantitative", "published_at": "2026-04-23T22:20:00", "published_display": "23 Apr 2026 22:20", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AgomAb Therapeutics (AGMB) Wins U.S. Patent for AGMB-447", "summary": "AgomAb Therapeutics NV (NASDAQ:AGMB) secured a U.S. patent for its investigational drug AGMB-447, an ALK5 inhibitor for idiopathic pulmonary fibrosis, providing protection through at least 2041. This news follows optimistic analyst coverage from Leerink and JPMorgan, who issued O", "url": "https://finance.yahoo.com/sectors/healthcare/articles/agomab-therapeutics-agmb-wins-u-184647133.html", "source_name": "Market source", "published_at": "2026-04-12T23:08:35", "published_display": "12 Apr 2026 23:08", "sentiment": "positive", "sentiment_pct": 74, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Agomab Therapeutics NV (AGMB) Stock Price Today: $12.31", "summary": "", "url": "https://news.google.com/rss/articles/CBMiV0FVX3lxTE5fWU12QldqQlFLc0pmVW5HMEhEXzhvcm9IcFhibmFZVU9XelRsUTlOV2Uxb0JEVGxZSng2NFZnT2JjQmpZMWtoYkJKdFJkRXFPODZvY2R3Yw?oc=5", "source_name": "Gotrade", "published_at": "2026-02-07T21:08:16+00:00", "published_display": "07 Feb 2026 21:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AgomAb Therapeutics NV Rings the Nasdaq Stock Market Closing Bell", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxQdU5zQ3Boa1lYSUlMU0lFSFp4Vk5IejFMcW1tNWVKTHRndFZIOFNrSFVZOGduSUZEcHVmM0VVTEh6OUhSWENyUk5qVkc3NG5nRUl1VEpTRDhJZnRtQjhDSmczNWgwemxUamZyV0MwczVlaU4tcXRKZzhTN01Tc2xadGV6MXhsTTdLaDJzOGJiUnl2ZndlNXc?oc=5", "source_name": "Nasdaq", "published_at": "2026-02-06T08:00:00+00:00", "published_display": "06 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AgomAb Therapeutics NV Rings the Closing Bell", "summary": "", "url": "https://news.google.com/rss/articles/CBMie0FVX3lxTFBIbXdTdnhSTDBVWk1FTlkwQTRnZTZDWk1PUDdFQ1ZBak4zV0lpS19ldUdfWFdLR3lEcnNsNWhjMGRyclNoTVJ2cGpuRWQ5RUs4clFUbmFtSV9JMkF0UjhhbUNjXzlfVXlUZ0p1eHZ5eW5pcVFhbTlNTzFvaw?oc=5", "source_name": "Nasdaq", "published_at": "2026-02-06T08:00:00+00:00", "published_display": "06 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Agomab, SpyGlass head to Nasdaq with IPOs totaling $350M", "summary": "", "url": "https://news.google.com/rss/articles/CBMijgFBVV95cUxPQmFIRVZ4VFhhQUNLU2pocGVCWUZPNkVIdjdtanZNMVlCUmNwWXdwejRSbWJkQmtuY2JoaEFXekQ3eW82WTFiOWhJQTBoVlBXZGNCMkJ1RExFUGFOX1pLT0ZVZEY5MWNFMVNUQUhHc1NvczByTWYxUVBERV81Q1NmcVFSSGp4b1NndjQ4eXlR?oc=5", "source_name": "Fierce Biotech", "published_at": "2026-02-06T08:00:00+00:00", "published_display": "06 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Agomab goes public on Nasdaq as biotech IPOs top $1bn in a single week", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxPNTFvbDFRNGlWNURySk5oRlBIZkNBeFNyNU9RWkZDYU9kMHRfNi1xRGRLTUluNHUwTFIyZG12YjBIbkIzLUhHZG8tVkRKb3VOemRTc3drNTE2V3dKU296enFmWTJYTjlEUXF4RUR1T2hMaG5kUG85dGgtbi15OU9PODVnYnBvSTA5Yjh6Y2oxR3dIdnlIZTdhREJRMUZyRk5kY0YxbGZSZjFTOGpoUm5nSmN1T0x6NGRV?oc=5", "source_name": "European Biotechnology Magazine", "published_at": "2026-02-06T08:00:00+00:00", "published_display": "06 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AgomAb Therapeutics NV (AGMB) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE40eVVER0FURm92V2JpLVpDeldmSU5PN3RMYjhWb0cwZVhIUk5hcGFYaUFiVWcwYm1jMHdGbTZVNHNKdmxwaUhGM0N2SlJxT1FhbW00?oc=5", "source_name": "Stock Titan", "published_at": "2026-02-06T04:27:58+00:00", "published_display": "06 Feb 2026 04:27", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AgomAb Therapeutics NV Readies US IPO On Early Promising Results (AGMB)", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxOZkMwUFZPcFY3WnkxaUdRaTBuLXo0MVVlN1RwUWY0Y3FKbTlOeVltWG40Q0tFdHlwMHpFNGVOQ201VzdEQl8xOGtEUE1LWl9OcTUtRDBfMEdtRm1qb0RzU0dTd0ppLTZlT2VnUERPYzkwYzV3eXZueXpKekhBS2pWVFltTEJ5SDRaWVJMU1FfZlJ5S3RTcXlkY3BuaVRBeDlhalpDVQ?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-01-29T08:00:00+00:00", "published_display": "29 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxOWWM3V1pmZzdlY1llRTljQmNLQ2UwdDdQaFVEcng2WVdrNE9qNzRrNVpBVlJNMGltQUhBUG1qellCVHNiM09fUkFHRW1kMEpvazJoLU11N3c4YnlWUXpmVl82aWNKeTA4U1RwSHNNSVd4d0lwWHRJclQ2TGNHWUpBQTgzbTBMVk05VGxYN0RwcmpTYklOQUFSWDhsSHZlQVpndmlPRGNvTmRmeHNILWg4ZE5jMjRoN01XNENiaVU2UDUyOWJfYUZCTm5URmtwTHJsTjJYNHo3RkxsQjBSMnBmdVZVWkFwN2PSAewBQVVfeXFMT3htM016bEt0TTdyOXE2amppMGpubTNfOFU4cGpxd2dFZkJDTjR3c0ZqOHpHYWZoamNLdmkxVmNYNklxTEM4NTU0bDZwUTZ1SW5Jc1c4NmRJN3lKQUVqUUNYYWptd2ZYNE9TeEhMRzFvbEt0bjk1TVhyVG44UnJnNDllTlFsalJVUTZwcEEzWXljbzdaQXdWWDlHQW56bGxqeG90UlFmaFFLekJlUlNIOVE4SGNHcE9pOW1KSllleVdwNERiaVl2NmxtNTNyaUtnSFY1VHUzcDJsWE9xb3R1ajZ2RGhkXzJzTldMOVA?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 83, "total_relevant": 49, "sentiment_summary": {"positive": 16, "negative": 3, "neutral": 30, "score": 57, "total": 49, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 76, "events": [{"event": "general", "label": "Market update", "weight": 11.9, "count": 21}, {"event": "earnings", "label": "Earnings", "weight": 8.46, "count": 17}, {"event": "analyst", "label": "Analyst action", "weight": 1.65, "count": 3}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 1.65, "count": 3}, {"event": "deals", "label": "Deals and strategy", "weight": 1.65, "count": 3}, {"event": "guidance", "label": "Guidance", "weight": 0.55, "count": 1}], "positive_events": 16, "negative_events": 3}, "market_context": {"has_market_context": true, "latest_close": 12.04, "latest_week": "2026-07-17", "one_week_move": -8.0, "four_week_move": 9.7, "twelve_week_move": 9.0, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 0.0, "market_dynamics_buy_signal": false, "relative_strength": null, "fair_value_gap": -1.8, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "undecided", "expectation_probability": 49.7512, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-8.0% over one week, +9.7% over four weeks, trend inactive, and near fair-value range."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 65, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 11}, {"label": "Market source", "count": 8}, {"label": "TradingView", "count": 6}, {"label": "Finviz", "count": 3}, {"label": "MT Newswires", "count": 2}, {"label": "Investing.com Nigeria", "count": 2}, {"label": "Seeking Alpha", "count": 2}, {"label": "The Manila Times", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 40}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 21}, {"label": "Earnings", "count": 17}, {"label": "Analyst action", "count": 3}, {"label": "Regulatory and legal", "count": 3}, {"label": "Deals and strategy", "count": 3}, {"label": "Guidance", "count": 1}, {"label": "Balance sheet", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "57/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "76/100 classification confidence."}, {"label": "Company focus", "value": "40", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "2", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-8.0% over one week, +9.7% over four weeks, trend inactive, and near fair-value range."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Enterprise value to EBIT forward of AgomAb Therapeutics NV \u2013 NASDAQ:AGMB"}], "updated_at": "2026-07-23T05:37:33.975381+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}